Orchard Therapeutics

45 articles with Orchard Therapeutics

• 

  BioSpace Movers and Shakers for Dec. 10

  12/10/2018

  Biotech and pharma companies strengthen their leadership teams with these appointments. Who made power moves in the industry this past week?

• Orchard Therapeutics Appoints Industry Veteran Alicia Secor to its Board of Directors

  12/7/2018

  Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced the appointment of Alicia Secor to its board of directors

• 

  Exclusive: Orchard CEO Touts Transformative Power of Gene Therapy Following ASH Data Presentation

  12/7/2018

  The word transformative is not used lightly by Orchard Therapeutics Chief Executive Officer Mark Rothera. He has seen the lives of children born with rare autoimmune diseases changed dramatically through gene therapies developed by his company.

• Donald B. Kohn, MD, Orchard Therapeutics Scientific Advisory Board Member, Presents Clinical Proof-of-Concept Data for OTL-102 Gene Therapy for the Treatment of Patients with X-CGD at the Presidential Symposium at the 2018 ASH Annual Meeting

  12/5/2018

  Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that Scientific Advisory Board Member, Donald B. Kohn, MD, presented clinical proof-of-concept data from an ongoing academic clinical trial evaluating OTL-102 for the treatment of X-Linked Chronic Granulomatous Disease

• 

  BioSpace Movers and Shakers Nov. 12

  11/12/2018

  Biopharma companies name new members of their leadership teams. Who made big moves this week?

• Orchard Therapeutics Strengthens Global Commercial Leadership Team with Appointments of Heads of US and EMEA Region Commercial Operations

  11/8/2018

  Commercial team preparing for potential gene therapy launches

• Orchard Therapeutics Announces Closing of $225 Million Initial Public Offering, Including the Partial Exercise of Underwriters' Option

  11/5/2018

  Orchard Therapeutics plc today announced the closing of its initial public offering of 16,103,572 American Depositary Shares (“ADSs”),

• 

  Updated: BioSpace's List of October 2018 Life Sciences IPOs

  10/31/2018

  A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.

• Orchard Therapeutics Announces Pricing of Initial Public Offering

  10/31/2018

   Orchard Therapeutics plc (Nasdaq: ORTX), today announced the pricing of its initial public offering in the United States of 14,285,715 American Depositary Shares (“ADSs”) representing 14,285,715 ordinary shares at an initial public offering price of $14.00 per ADS, before underwriting discounts and commissions.

• 

  A Look Back at October Life Sciences IPOs

  10/31/2018

  October was a busy month as multiple biopharma companies made their debut as publicly traded entities and even more companies filed their intentions to go public with an initial public offering. BioSpace takes a look back at some of the key IPOs of the month.
• 

  Orchard Therapeutics: PRIME Designation in Europe and an IPO Registration

  10/5/2018

  Orchard Therapeutics, with locations in Boston and London, UK, received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for OTL-300, a lentiviral gene therapy for transfusion-dependent beta-thalassemia (TDBT).

• Orchard Therapeutics Receives EMA PRIME Designation for OTL-300, an Investigational Lentiviral Gene Therapy for the Treatment of Transfusion-Dependent Beta-Thalassemia

  10/4/2018

  Orchard Therapeutics today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to OTL-300, an investigational autologous ex vivo lentiviral gene therapy for the treatment of transfusion-dependent beta-thalassemia (TDBT), the most severe form of beta-thalassemia.

• 

  Movers and Shakers for Sept. 4

  9/4/2018

  Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let's take a look.

• Orchard Therapeutics Expands Leadership Team with Appointments of Head of Corporate Communications and Head of Human Resources

  8/29/2018

  Orchard Therapeutics, a leading commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced two additions to its ex­­­ecutive leadership team.

• Kymriah® (tisagenlecleucel, formerly CTL019) receives European Commission Approval

  8/28/2018

  Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the European Commission (EC) has approved the Novartis CAR-T cell therapy, Kymriah® (tisagenlecleucel, formerly CTL019).

• 

  Taking a Look at Trends in Biotherapeutics

  8/15/2018

  It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs.
• 

  Orchard Therapeutics Nabs $150 Million in Series C Funding

  8/13/2018

  Four months after acquiring GlaxoSmithKline’s rare disease gene therapy portfolio, U.K.-based Orchard Therapeutics secured $150 million in an oversubscribed Series C funding round. The funds will be used to advance three late-stage programs that it gained from the deal with GSK.

• Orchard Therapeutics Announces $150 Million Series C Financing to Advance Gene Therapy Pipeline

  8/13/2018

  Orchard Therapeutics, a leading commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the completion of an oversubscribed $150 million Series C financing.

• Orchard Therapeutics Appoints Jon Ellis to Board of Directors

  8/2/2018

  Orchard Therapeutics, a leading commercial-stage biotech company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the appointment of Jon Ellis, Ph.D. as GSK’s designated representative to its board of directors.

• 

  Biotech Movers and Shakers for July 16

  7/16/2018

  With the Independence Day holiday in the rearview mirror, numerous biopharma companies continued to adjust their leadership ranks and strengthen the members of various boards representing and overseeing the companies.